Glenmark molecule to enter human trials in Netherlands

Glenmark Pharmaceuticals has filed an application in Netherlands for human trials on its molecule ‘GRC 17536’, which aims to treat pain and respiratory disorders. The company has completed animal trials on its novel chemical entity (NCE) GRC 17536 and has filed the Phase I application for first-in-man trial in Netherlands, Glenmark Pharmaceuticals.

The total market for asthma and chronic lung disease is about $30 billion and for osteoarthritis and neuropathic pain, it is nearly $10 billion. There is a huge unmet medical need in both therapeutic areas globally. crackcrack